Caffeic acid phenethyl ester (CAPE) confers wild type p53 function in p53Y220C mutant: bioinformatics and experimental evidence

Navaneethan Radhakrishnan1 · Jaspreet Kaur Dhanjal2,3 · Anissa Nofita Sari2 · Yoshiyuki Ishida4 · Keiji Terao4 · Sunil C. Kaul2 · Durai Sundar1 · Renu Wadhwa2

Received: 29 September 2021 / Accepted: 7 December 2021
Published online: 20 December 2021
© The Author(s) 2021
OPEN

Abstract
Mutations in the tumor suppressor protein p53 is a prevalent feature in majority of cancers resulting in inactivation of its activities related to control of cell cycle progression and proliferation. p53Y220C is one of the common hotspot mutations that causes decrease in its thermodynamic stability. Some small molecules have been shown to bind to the mutated site and restore its wild type thermodynamics and tumor suppressor function. In this study, we have explored the potential of caffeic acid phenethyl ester (CAPE—a bioactive compound from propolis) to interact with p53Y220C and restore its wild type p53 (p53wt) transcription activation and tumor suppressor activities. We recruited computational methods, viz. molecular docking, molecular dynamics simulations and free energy calculations to study the interaction of CAPE at the mutation crevice and found that it has potential to restore p53wt function of the p53Y220C mutant similar to a previously described restoration molecule PK7242. We provide cell-based experimental evidence to these predictions and suggest CAPE as a potential natural drug for treatment of p53Y220C mutant harboring cancers.

Keywords  p53Y220C · CAPE · p53wt · Restoration · Anticancer · Therapy

1 Introduction
Cancer is a complex disorder. Commonly defined as a disease of proliferation, it is an outcome of large number of molecular changes in cells yielding activation of oncogenes and/or inactivation of tumor suppressor genes and involves intricate network of interactions between the tumor and host tissue. Among the various genetic aberrations
leading to the onset and progression of carcinogenesis, functional inactivation of p53 tumor suppressor protein (by mutations or other mechanisms) has been found in almost every type of cancer. However, the rate of mutagenesis varies greatly—from 10% in hematopoietic malignancies to almost 100% in high-grade serous carcinoma [1]. p53, also known as the guardian of genome, plays key role in tumor suppression by inducing growth arrest, apoptosis and senescence [2–4]. Wild type p53 activities, besides proliferation, have also been shown to inhibit cancer metastasis [5], the process of angiogenesis [6] and sensitize the cancer cells to chemotherapeutic agents [7]. Advances in high-throughput sequencing of cancer genomes have led to the identification of p53 mutational signatures with clinical significance. Based on various crystallographic studies on p53 mutants, these can mainly be classified in three categories—(i) contact mutations occurring in the DNA-binding region of p53 protein (like mutations involving amino acid residues R273 and R248), (ii) structural mutations causing conformational instability in p53 protein (like mutations involving amino acid residues R175, G245, R249 and R282), and (iii) oncomorphic mutations leading to the loss of wild type p53 function whilst the gain of oncogenic properties (mutations involving residues R248, R273 and R175). Therefore, mutations in p53 may inactivate or differently activate the molecule. p53YW220C is one of the frequently observed mutant forms of p53 in cancer cells [8], p53YW220C mutant contains a unique surface crevice, formed due to the replacement of tyrosine with cysteine at 220th amino acid residue position [9]. The solvation of this crevice decreases the thermodynamical stability and hence the activity of the protein [10, 11]. It has been reported that this surface crevice is druggable, and hence the mutant can be rescued by small molecules that can bind to the crevice and stabilize the molecule [9, 12]. As this crevice is distant from the DNA-binding interface or any other protein–protein interaction interfaces of p53, small molecules can interact with the mutation crevice without interfering with binding of the protein to its interacting partners [12, 13]. Different synthetic molecules like PhiKan 083, PK7088, PK7242 and MB725 have been reported to cause reactivation of the mutant by binding to the mutation crevice [9, 12, 13]. Since introduction of wild type p53 activity in mutant p53 harboring cancer cells causes their growth arrest/apoptosis, the anticancer therapies targeting mutant p53/activation of wild type p53 function have been considered as a valid and effective drug discovery approach. Not only small molecules, other approaches like introduction of mutation at secondary site [14], use of antibodies [15, 16] or short peptides [17, 18] have also been reported to restore DNA binding in the mutant p53 protein resulting in activation of its transcriptional and tumor suppressor functions. A previous study from our group has also shown the potential of withanolides, withaferin-A and withanone, in restoring the wild type p53 activity in p53YW220C mutant harboring cancer cells [19].

Caffeic acid phenethyl ester (CAPE) is a bioactive compound extracted from honeybee propolis. Recent studies have shown that CAPE possesses anticancer activity against a variety of cancer types and is more toxic to cancer in comparison to healthy cells [20–22]. The potential anticancer activity of CAPE has been attributed to various mechanisms of its action that involve—(i) inhibition of NF-kappa B, iNOS signaling, PAK1 and histone deacetylase [23–27], (ii) restoration of gap junctions and downregulation of p21ras [28, 29] (iii) induction of apoptosis by regulation of p53, Bax and Bak [30–32], (iv) targeting VEGF mediated processes like angiogenesis, invasion and metastasis [33, 34], (v) controlling epithelial–mesenchymal transition by modulating Vimentin and Twist 2 [12], (vi) downregulation of Akt signaling pathway [35–37], and (vii) abrogation of mortalin-p53 interactions causing nuclear translocation and reactivation of the transcriptional activation function of p53 resulting in growth arrest of cancer cells [38]. Further, it has also been shown to inhibit cell migration, sensitize cancer cells to other chemotherapeutic agents [39–41] and act as radioprotector and radiosensitizer [42].

We had earlier reported that CAPE causes downregulation of mortalin and also blocks its interaction with p53, resulting in reactivation of its transcriptional activation function [38, 43]. CAPE-treated cells showed nuclear translocation and enrichment of wild type p53. This phenomenon was accompanied by activation of wild type p53 transcriptional activation function, upregulation of p21WAFI and growth arrest in cancer cells [38, 43]. In the present study, we investigated its effect on p53YW220C mutant. Molecular modelling methods of docking and molecular dynamics simulations were used to examine the interaction of CAPE with p53YW220C, assuming that CAPE could cause reactivation of p53YW220C by binding to its mutation crevice like some other reported small molecules including aminobenzothiazole derivatives and Ashwagandha withanolides, withaferin-A and withanone [9, 12, 13, 19]. Bioinformatics and experimental analyses revealed that CAPE could confer wild type p53 function to p53YW220C yielding growth arrest/apoptosis in cancer cells.
2 Materials and methods

2.1 Molecular structure of proteins and ligand

The three-dimensional structures of the proteins were downloaded from Protein Data Bank (www.rcsb.org). The PDB identifiers of the p53 structures are 3ZME and 1UOL [44, 45]. 3ZME is the p53Y220C mutant with the stabilizing molecule PK7242 bound to its mutation crevice. 3ZME was used for analyzing the interaction of CAPE in the mutation crevice with reference to that of the bound PK7242. 1UOL is a stable-variant of p53 structurally and functionally similar to wild-type. 1UOL was used as a wild-type representative for comparison with the equilibrated structures of CAPE-bound p53Y220C and PK7242-bound p53Y220C. The three-dimensional structures of CAPE and PK7242 were downloaded from PubChem database (CID: 5281787 and CID: 91885429 respectively). The proteins were prepared using Schrodinger Maestro Suite 2020 [46]. Hydrogens were added and bond orders were assigned in the protein structure. Ionization state ‘2+’ was assigned for the zinc atom that was present in both the crystal structures of p53. Missing side chains of the residues were added. N and C termini were capped using N-acetyl and N-methyl amide groups respectively. PROPKA was used to assign the protonation states corresponding to pH of 7 [46]. The ionization states of ligands at target pH of 7 were generated and optimized using LigPrep module in Maestro [46].

2.2 Generation of protein-drug complexes by molecular docking

The Glide module in Maestro was used for the docking of CAPE and PK7242 to the mutation crevice of p53Y220C [46]. Docking grid of dimensions 10 Å on each side was generated around residue 220 of p53Y220C and the ligands were docked using the Extra-precision (XP) docking and scoring method in Glide [46]. Flexible ligand docking was used, and the top scoring docking poses were chosen for further analysis.

2.3 Molecular dynamics simulation of p53Y220C—drug complexes

To account for the stability of the interacting protein and ligand in a dynamic aqueous environment and study the resulting structural changes, the docked complexes were subjected to molecular dynamics simulations. All the molecular dynamics (MD) simulations were performed in Desmond using OPLS3e force field [46]. The mutant and stable-variants of p53 protein and, protein-drug complexes were solvated in water boxes. TIP3P water model was used. NaCl was used to neutralize the system and an additional concentration of 0.15 M was added. After system generation, Brownian motion simulation was done for 100 ps to minimize the systems. The systems were relaxed using relaxation protocol in Maestro, in which the following series of simulations were performed: Brownian dynamics simulations for 100 ps at 10 K with restraints on solute heavy atoms; MD simulations in NVT ensemble at 10 K with restraints on solute heavy atoms for 12 ps using Langevin thermostat; simulation in NPT ensemble for 12 ps with restraints for solute heavy atoms at 10 K at 1 atm pressure using Langevin thermostat and Langevin barostat; simulation in NPT ensemble for 12 ps with restraints for solute heavy atoms at 300 K and 1 atm pressure using Langevin thermostat and Langevin barostat; and simulation in NPT ensemble for 24 ps at 300 K and 1 atm pressure using the same thermostat and barostat [46]. After relaxing the system, production MD simulations were performed in NPT ensemble with a timestep of 2 fs. Restraints were not applied to any atoms. Nose–Hoover chain method was used to maintain temperature at 310 K, and pressure was maintained at 1 atm using Martyna-Tobias-Klein barostat [46]. For each system, simulation was performed for 200 ns and the data from last 100 ns were used for all the analyses.

2.4 Energy calculations

All the energy calculations were done using Prime module in Maestro [46]. Prime performs single-point molecular mechanics energy calculation using OPLS3e force field and VSGB 2.0 energy model [46]. The protein–ligand binding free energies are computed using Prime MM-GBSA.

2.5 Cell lines and reagents

Human isogenic hepatocarcinoma HuH-6 (representative of wild type p53) and HuH-7 (harboring Y220C p53 mutation) cells were purchased from the Japanese Collection of Research Bioresources (JCRB Cell Bank, Tokyo, Japan). Cells were
cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco BRL, Grand Island, NY, USA) supplemented with 5% fetal bovine serum (Fujifilm WAKO Pure Chemical Corporation, Osaka, Japan) and 1% antibiotics (penicillin–streptomycin) in 5% CO₂ and 95% air humidified incubator.

2.6 Cell viability assay

Cells were seeded into 96-well plate (5000 cells/well) and incubated for 24 h. The following day, CAPE (5–30 μM) was added to the culture medium for next 24 h followed by cell viability assay using MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) (Sigma Aldrich, Tokyo, Japan) following the manufacturer's instructions. Control and CAPE treated cells were incubated with MTT (0.5 mg/ml) at 37 °C, 5% CO₂ for 4 h. MTT-containing medium was replaced with DMSO (100 μl) in each well. Absorbance of the blue chromogen was measured at 570 nm using a spectrophotometer (Tecan Group Company Ltd., Männedorf, Switzerland).

2.7 Luciferase reporter assays

PG13-Luc plasmid (bearing 13 repeats of the p53WT binding sequence) was a kind gift from Professor Bert Vogelstein. pWWP-Luc carrying the full p21WAF-1 promoter was purchased from AddGene, MA USA. The plasmids were transiently transfected into HuH-6 and HuH-7 cells using X-tremeGENE 9 HP DNA (Roche, Basel, Switzerland), following the manufacturer's protocol. In brief, cells were plated into a 6-well plate, and 3 μg of each plasmid was transfected into cells at a ratio of 3:1 of transfection reagent to DNA in antibiotic-free Opti-MEM (Invitrogen) media. The cells were cultured in serum-free media for 12–15 h after which serum-free media was replaced with complete growth media for the recovery of cells. After 24 h, some cells were taken to examine the transfection efficacy by firefly luciferase assay using untransfected cells as a control. Rest of the cell were seeded in a 6-well plate and allowed to adhere to substratum overnight. Next day, cells were treated with 10 μM and 30 μM CAPE for 24 h followed by preparation of lysates in passive lysis buffer. The luciferase activity was measured using firefly luciferase assay from Dual-Luciferase reporter assay system kit (Promega, WI, USA) and Infinite 200 PRO, luminescent plate reader (Tecan infinite M200® Pro) (Männedorf, Switzerland) and was normalized/µg of the protein.

2.8 Western blotting

Control and CAPE-treated cells were harvested after 24 h, lysed using RIPA Lysis Buffer (Thermo Fisher Scientific, Waltham, MA, USA) containing complete protease inhibitor cocktail (Roche Applied Science, Mannheim, Germany) and shaken in a cold room for 30 min. Lysates were centrifuged at 15,000 rpm for 15 min, and the supernatants were used for the Western-blotting analysis. The protein concentrations of whole-cell lysates were measured by the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA). The cell lysates (10–40 μg) were separated in 6–15% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a polyvinyl dene difluoride (PVDF) membrane (Millipore, Bilerica, MA, USA) using a semi-dry transfer blotter (ATTO Corporation, Tokyo, Japan). Membranes were blocked with 3% fraction-V bovine serum albumin at room temperature for 2 h. Blocked membranes were probed with the following target protein-specific primary antibodies: p53 (DO-1), BAX (H20X) (Santa Cruz Biotechnology, Paso Robles, CA, USA); Mortalin (376) (raised in our laboratory); and p21WAF1 (12D1) (Cell Signaling Technology, Danvers, MA, USA) at 4 °C overnight. The blots were incubated with the following secondary antibodies conjugated to horseradish peroxidase: anti-rabbit IgG, anti-goat IgG, and anti-mouse IgG (Santa Cruz Biotechnology, CA, USA) and developed by enhanced chemiluminescence (ECL) (GE Healthcare, Buckinghamshire, UK). Anti-β-actin antibody (Abcam, Cambridge, UK) was used as an internal loading control. ImageJ (National Institutes of Health, Bethesda, MD, USA) software was used to quantitate the protein signals.

2.9 Statistical analysis

The mean and standard deviation of data from three or more independent experiments were calculated. The degree of significance between the control and treated experimental samples was determined using an unpaired t-test (GraphPad Prism GraphPad Software, San Diego, CA, USA). Statistical significance was defined as non-significant (**p value < 0.05), significant (*p value ≤ 0.05), very significant (**p value ≤ 0.01), and highly significant (**p value ≤ 0.001).
3 Results

Y220C is a common mutation observed in p53 across various cancer types [47]. The replacement of tyrosine by cysteine causes disruption in the hydrophobic core maintained by the benzene ring of tyrosine, creating a surface crevice [9]. This leads to thermodynamically unstable p53 structure. However, as mentioned, it is possible to restore the structural stability in these mutant proteins. Therefore, here we explored the potential of CAPE to rescue the mutant p53Y220C by binding to its crevice.

3.1 PK7242 and CAPE have a similar interaction pattern with p53Y220C

The crystallized complex of p53Y220C mutant with the small molecule PK7242 bound to its mutation crevice was taken as a reference system for molecular modelling studies [44]. Molecular analysis was done to analyze the docking of CAPE in PK7242-binding site/mutation crevice of p53Y220C. Firstly, PK7242 was re-docked into the mutation crevice of p53Y220C, and the binding pose obtained was compared with pose in the crystal structure to check for the closeness. The pyrrole moiety of PK7242 in both the cases was buried in the protein cavity and the pyrazole ring was sandwiched between the loops bordering the cavity (Supplementary Fig. 1). The molecular interaction pattern was also the same. The docking score thus obtained served as a reference for comparing CAPE binding, and it also validated the docking method used in the study. We found that similar to PK7242, CAPE also docked well within the p53Y220C mutation crevice (Fig. 1A). Interestingly, docking score of CAPE was higher as compared to that of PK7242 (Table 1). As shown in Fig. 1B, the docking pose of PK7242 was similar to its pose in the crystal structure (PDB 3ZME) [44], and the interactions were mostly hydrophobic (as shown in the two-dimensional interaction plot in Fig. 1C). CAPE formed two hydrogen bonds with the residues in the crevice (C220 and T150) of p53Y220C along with other hydrophobic interactions (Fig. 1D and E). Based on the docking score and molecular interactions, CAPE was found to be a better fit for the crevice of p53Y220C as compared to PK7242.

To further confirm the stability of these observed molecular interactions we used molecular dynamics simulations (MDS). MDS was performed for four different systems: p53 stable-variant (wild type representative), p53Y220C, p53Y220C + CAPE and p53Y220C + PK7242. The simulated structures in all the four cases were stable as reflected by the root mean square deviation (RMSD) calculated for heavy atoms of protein and ligand with respect to the initial structure throughout the 200 ns time scale of simulations (Fig. 2A). RMSD converged and hence we used the simulation data from last 100 ns for detailed analysis.

The number of hydrogen bonds between the small molecules—CAPE and PK7242 and mutant p53 during the course of simulation is shown in Fig. 2B. Since there were no hydrogen bonds between the ligands and the protein for substantial duration in the simulation trajectory, we can suggest that the hydrophobic interactions play major role in stabilizing the CAPE-p53Y220C interactions. Throughout the simulation, the hydrophobic phenethyl group of CAPE was found buried inside the hydrophobic core of the crevice, while its hydrophilic caffeic acid group interacted with the protein residues surrounding the crevice and water molecules. Figure 2C shows the interactions of CAPE with different residues in the crevice of p53Y220C during the simulation. The term ‘interactions fraction’ indicates the fraction of simulation time (100 ns) for which interaction of ligand with a specific residue of protein was maintained. Majority of the interactions of CAPE with the protein were found to be through hydrophobic contacts and water bridges, which differs from that of PK7242 where the water bridges were relatively less dominant/abundant suggesting that water molecules might also play an important role in mediating the CAPE-p53 interactions.

3.2 CAPE binding provided stability to p53Y220C structure

We next performed binding energy analysis of CAPE and PK7242 with p53Y220C using the last 100 ns of simulation trajectories. It was found that magnitude of binding free energy was higher for CAPE compared to that of PK7242 (Table 1). Hence, it was predicted that the CAPE has higher binding affinity for crevice of p53Y220C. Further, we also examined the PRIME energies of the optimized free wild type and mutated protein structure and the protein–ligand...
complexes (p53-stable variant, p53Y220C without any ligand, p53Y220C with PK7242/CAPE, respectively) (Fig. 3A). These relative energy terms allowed comparison of free and ligand bound states of the protein to analyze favorable energetics. Among all the four states, energy of p53Y220C + CAPE complex was the least suggesting that CAPE binding offers better stability to p53Y220C as compared to PK7242.

To study the structural changes in p53Y220C due to CAPE binding, the drug bound complexes were compared with p53-stable variant. The zinc ion held on to the p53 molecule in all the simulated systems. A representative structure was chosen from each of the simulation trajectory, and these structures were superimposed using Maestro suite [46]. After superimposition by the heavy atoms of protein backbone, RMSD between the structures were calculated. RMSD between superimposed p53Y220C + CAPE complex and p53Y220C + PK7242 complex was just 2.96 Å indicating that structural alterations induced by CAPE binding were not very different compared to that of PK7242 binding (Fig. 3B). RMSD of p53-stable variant structure superimposed with p53Y220C + CAPE and p53Y220C + PK7242 complexes were 2.75 Å and 3.18 Å, respectively (Fig. 3C). Lower RMSD of p53Y220C + CAPE complex with respect to p53-stable variant also confirmed the overall structural integrity of the CAPE bound mutant.

3.3 Experimental evidence of wild-type like activity in p53Y220C upon CAPE treatment

Next, we set out to experimentally validate the predictions by studying the effect of CAPE on cells expressing p53wt (HuH-6) and p53Y220C (HuH-7) proteins. As shown in Fig. 4A both HuH-6 and HuH-7 cells showed cytotoxicity of CAPE. Of note, HuH-7 cells containing p53Y220C showed stronger cytotoxicity in comparison to HuH-6 cells containing p53wt in the range of 5 to 30 μM CAPE treatments. Based on the cytotoxicity profile, we chose 10 and 30 μM dose of CAPE for further experiments.

In light of the information that p53Y220C is structurally unstable and transcriptionally inactive due to lack of its binding to DNA, we subjected HuH-6 and HuH-7 control and CAPE-treated cells to p53wt-driven luciferase reporter assays. As expected, p53wt-driven luciferase reporter activity was enhanced in CAPE treated HuH-6 cells (Fig. 4B). Interestingly, increase in p53wt-driven luciferase reporter activity was also observed in CAPE-treated HuH-7 cells (Fig. 4C). In order to further investigate whether CAPE-mediated reactivation of p53wt-function in HuH-7 cells could effectively initiate its downstream signaling pathways, we next carried out p21WAF−1 promoter-dependent luciferase reporter assay. As shown in Fig. 4D and E, both HuH-6 and HuH-7 cells showed remarkable increase in p21-promoter dependent luciferase reporter activity in CAPE (30 μM) treated cells.

We also performed Western blotting for proteins involved in p53wt-driven control of cell cycle and growth arrest in control and CAPE treated HuH-6 and HuH-7 cells. It is well established that mortalin, a heat shock protein enriched in cancer cell, sequestrates p53 in the cytoplasm, restricting its translocation to nucleus and hence the transcriptional activation function [48]. It was previously shown that CAPE abrogates mortalin- p53 interaction causing its translocation and reactivation of transcriptional activation function and growth arrest/apoptosis of cells mediated by specific downstream effectors [38]. In view of this, we examined the expression of mortalin and p53 in control and CAPE treated HuH-6 and HuH-7 cells. As shown in Fig. 5A and B, the expression of mortalin decreased in a dose-dependent manner in both the cell lines and was consistent with earlier reports [38, 43]. Of note, whereas HuH-6 cells showed 2–3 folds increase in p53wt protein, HuH-7 cells did not show any significant change in p53 protein level in several independent experiments.

Table 1 Docking scores and calculated free energies of binding of CAPE and PK7242 at p53Y220C mutation crevice (the errors indicate the standard error of the mean)

|                | CAPE       | PK7242    |
|----------------|------------|-----------|
| Docking score  | −9.115     | −6.611    |
| Free energy of binding (kcal/mol) | −60.31 ± 0.10 | −43.44 ± 0.09 |
Fig. 2 Analysis of molecular dynamics simulation trajectories. (A) Root mean square deviations of heavy atoms in the simulated structures with respect to the starting structure over 200 ns of simulation run. (B) Number of hydrogen bonds formed between the ligands and p53Y220C crevice during the last 100 ns of each simulation. Interactions fraction diagram of CAPE (C) and PK7242 (D) at the mutation crevice of p53Y220C. The fraction of simulation time during which hydrogen bonds, hydrophobic contacts, ionic contacts, and water bridges are retained with different residues at the mutation crevice of p53Y220C is shown in these plots.
In order to assess p53wt function, we investigated the expression of p21WAF−1 and BAX, downstream genes in p53 pathway involved in cell cycle arrest and apoptosis respectively. In line with the reactivation of transcriptional-activation function of p53wt in CAPE treated cells, p21WAF−1 and BAX proteins showed upregulation in the treated HuH-6 cells. Of note, remarkable increase in expression of these proteins were observed in HuH-7 cells demonstrating restoration of p53wt function in p53Y220C cells by CAPE.

4 Discussion

CAPE has earlier been shown to possess anticancer potential for a variety of cancer cell types. It caused activation of DNA damage response, upregulation of GADD45 and reactivation of tumor suppressor p53 in cancer cells [38, 43]. The p53 protein is the most mutated protein across various cancer types. The loss-of-function mutations in p53 either directly disrupt its interaction with DNA or make the structure unstable effecting its transcriptional activation function. Hence, there is a need to check the response of p53 targeting drugs on these mutant variants to account for wider applicability. We investigated the potential of CAPE for its effect on p53Y220C mutant. The higher affinity of CAPE to p53Y220C crevice as compared to the known co-crystallized binder and restoration small molecule—PK7242 (as evident through the binding free energy calculations) indicated that p53Y220C could be targeted by CAPE in cancer cells. Molecular dynamics simulations analyses showed that CAPE-p53Y220C interactions were stable. As the solvation of the crevice in p53Y220C has been attributed to the destabilization of the p53 molecule, the association of hydrophobic phenethyl group of CAPE with the crevice prevented its solvation and thereby stabilized the molecule. The degree of stabilization was found to be higher in case of CAPE, compared to PK7242, as suggested by PRIME energy calculations. RMSD calculations after superimposing the equilibrated structures of CAPE-bound p53Y220C with the stable-variant did not show any significant alterations in the complexes after binding with ligands and subsequent simulations.

Fig. 3 PRIME energies and structural integrity of the simulated complexes. (A) PRIME energies of p53 stable-variant, p53Y220C, p53Y220C + CAPE complex and p53Y220C + PK7242 complex during last 100 ns of simulation. CAPE bound to p53Y220C had the lowest PRIME energy. The error bars indicate standard error of the mean. (B) Structure of CAPE-bound p53Y220C (purple) superimposed with structure of PK7242-bound p53Y220C (green). (C) Structures of CAPE-bound p53Y220C (purple) and PK7242-bound p53Y220C (green) superimposed with structure of the p53 stable-variant (yellow). The RMSD of the superimposed structures did not indicate any significant structural alterations in the complexes after binding with ligands and subsequent simulations.
Fig. 4 Activation of wild type like p53 activity in p53 mutant cell line. (A) Dose dependent cytotoxicity of CAPE in HuH-6 and HuH-7 cells. (B–E) Detection of p53<sup>wt</sup>-dependent luciferase activity by reporter plasmids containing the p53-binding synthetic sequence (PG-13Luc) (B, C) of p21<sup>WAF<sub>1</sub></sup>-promoter (WWP-Luc) (D, E). Increase in p53<sup>wt</sup>-dependent luciferase activity was detected in CAPE treated HuH-6 cells (B, D) and HuH-7 (C, E) cells showed stronger effect on HuH-7 cells. Wild type p53<sup>wt</sup>-dependent synthetic (PG-13Luc) and p21<sup>WAF<sub>1</sub></sup>-promoter (pWWP-Luc) reporter assays revealed increase in reporter activity both in HuH-6 and HuH-7 cells. Reactivation of wild type p53 (HuH-6) was in line with other cancer cell types (MCF7, U2OS) [38]. Furthermore, wild type p53 activity in HuH-7 cells supported the bioinformatics analysis. CAPE-treated cells also showed increase in expression of p21<sup>WAF<sub>1</sub></sup> and BAX proteins that are involved in p53<sup>wt</sup>-induced growth arrest or apoptosis, respectively. These data demonstrated that CAPE caused restoration of p53<sup>wt</sup> in HuH-7 cells that possess p53<sup>Y220C</sup>. 
5 Conclusion

In this study we explored the potential of CAPE to restore the function of structurally unstable p53\textsuperscript{Y220C}. Molecular docking, molecular dynamics simulations and free energy calculations revealed that CAPE could bind to the mutation crevice in p53\textsuperscript{Y220C} and re-established the hydrophobic core disrupted by the mutation. Cell-based molecular assays further demonstrated reactivation of p53\textsuperscript{wt} function yielding growth arrest/apoptosis in p53\textsuperscript{Y220C} harboring cells. CAPE is suggested as a potential natural small molecule drug for treatment of p53\textsuperscript{Y220C} harboring cancers.

Authors’ contributions  Conceptualization: DS and RW; Methodology: NR, JKD and ANS; Formal analysis and investigation: NR, JKD, DS, ANS and RW; Writing-original draft preparation: NR, JKD, ANS and RW; Writing-review and editing: NR, JKD, DS, ANS, YI, KT, SK and RW; Funding acquisition: DS, SCK and RW; Resources: NR, JKD, DS, ANS, YI, KT, SK and RW; Supervision: DS, SCK and RW. All authors read and approved the final manuscript.

Funding  This study was supported by the funds granted by Department of Biotechnology (DBT), Govt. of India and the National Institute of Advanced Industrial Science and Technology (AIST), Japan.

Data availability  All data generated or analyzed during this study are included in this published article.

Declarations

Competing interests  The authors declare no competing interests.

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References

1. Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes Cancer. 2011;2:466–74. https://doi.org/10.1177/1947609111408889.

2. Ozaki T, Nakagawara A. Role of p53 in cell death and human cancers. Cancers. 2011;3:994–1013. https://doi.org/10.3390/cancers3010994.

3. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol. 2008;9:402–12. https://doi.org/10.1038/nrm2395.

4. Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature. 2009;458:1127–30. https://doi.org/10.1038/nature07986.

5. Powell E, Piwnica-Worms D, Piwnica-Worms H. Contribution of p53 to metastasis. Cancer Discov. 2014;4:405–14. https://doi.org/10.1158/2159-8290.CD-13-0136.

6. Teodoro JG, Evans SK, Green MR. Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J Mol Med (Berl). 2007;85:1175–86. https://doi.org/10.1002/sm.20221.

7. Zhang Y, Han CY, Duan FG, Fan XY, Yao XJ, Parks RJ, Tang YJ, Wang MF, Liu L, Tsang BK, et al. p53 sensitizes chemoresistant non-small cell lung cancer via elevation of reactive oxygen species and suppression of EGFR/Pi3K/AKT signaling. Cancer Cell Int. 2019;19:188. https://doi.org/10.1186/s12933-019-0910-2.

8. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Ollivier M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007;28:622–9. https://doi.org/10.1002/hum.20495.

9. Boeckler FM, Joerger AC, Jaggi G, Rutherford TJ, Veprintsev DB, Fersht AR. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci USA. 2008;105:10360–5. https://doi.org/10.1073/pnas.0805326105.

10. Bullock AN, Henckel J, Fersht AR. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene. 2000;19:1245–56. https://doi.org/10.1038/sj.onc.1203434.

11. Joerger AC, Ang HC, Fersht AR. Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc Natl Acad Sci USA. 2006;103:15056–61. https://doi.org/10.1073/pnas.0607286103.

12. Chen MJ, Shih SC, Wang HY, Lin CC, Liu CY, Wang TE, Chu CH, Chen YJ. Caffeic Acid phenethyl ester inhibits epithelial-mesenchymal transition of human pancreatic cancer cells. Evid Based Complement Alternat Med. 2013;2013:270906. https://doi.org/10.1155/2013/270906.

13. Baud MGJ, Bauer MR, Verducì L, Dingler FA, Patel KJ, Horil Roy D, Joerger AC, Fersht AR. Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53–Y220C cell lines. Eur J Med Chem. 2018;152:101–14. https://doi.org/10.1016/j.ejmech.2018.04.035.

14. Nikolova PV, Wong KB, DeDecker B, Henckel J, Fersht AR. Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations. EMBO J. 2000;19:370–8. https://doi.org/10.1093/emboj/19.3.370.

15. Abarzuza P, LoSardo JE, Gubler ML, Neri A. Microinjection of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53. Cancer Res. 1995;55:3490–4.

16. Caron de Fromentel C, Gruel N, Venot C, Debussche L, Conseiller E, Dureuil C, Teillaud JL, Tocque B, Bracco L. Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments. Oncogene. 1999;18:551–7. https://doi.org/10.1038/sj.onc.1202338.

17. Friedler A, Hansson LO, Veprintsev DB, Freund SM, Rippin TM, Nikolova PV, Proctor MR, Rudiger S, Fersht AR. A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc Natl Acad Sci USA. 2002;99:937–42. https://doi.org/10.1073/pnas.241629998.

18. Selivanova G, Iotsova V, Okan I, Fritsche M, Strom M, Groner B, Graefstrom RC, Wiman KG. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat Med. 1997;3:632–8. https://doi.org/10.1038/nm0697-632.

19. Sundar D, Yu Y, Katiyar SP, Putri JF, Dhanjal JK, Wang J, Sari AN, Kolettas E, Kaul SC, Wadhwa R. Wild type p53 function in p53(Y220C) mutant harboring cells by treatment with Ashwagandha derived anticancer withanolides: bioinformatics and experimental evidence. J Exp Clin Cancer Res. 2019;38:103. https://doi.org/10.1186/s13046-019-1099-x.

20. Frenkel K, Wei H, Bhimani R, Ye J, Zadunaisky JA, Huang MT, Ferraro T, Conney AH, Grunberger D. Inhibition of tumor promoter-mediated processes in mouse skin and bovine lens by caffeic acid phenethyl ester. Cancer Res. 1993;53:1255–61.

21. Su ZZ, Lin J, Grunberger D, Fisher PB. Growth suppression and toxicity induced by caffeic acid phenethyl ester (CAPE) in type 5 adenovirus-transformed rat embryo cells correlate directly with transformation progression. Cancer Res. 1994;54:1865–70.

22. Jin UH, Chung TW, Kang SK, Suh SJ, Kim JK, Chung KH, Gu YH, Suzuki I, Kim CH. Caffeic acid phenyl ester in propolis is a strong inhibitor of matrix metalloproteinase-9 and invasion inhibitor: isolation and identification. Clin Chim Acta. 2005;362:57–64. https://doi.org/10.1016/j.cca.2005.05.009.

23. Natarajan K, Singh S, Burke TR Jr, Grunberger D, Aggarwal BB. Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappaB. Proc Natl Acad Sci USA. 1996;93:9090–5. https://doi.org/10.1073/pnas.93.17.9090.

24. Song YS, Park EH, Hur GM, Ryu YS, Lee YS, Lee JY, Kim YM, Jin C. Caffeic acid phenethyl ester inhibits nitric oxide synthase gene expression and enzyme activity. Cancer Lett. 2002;175:53–61. https://doi.org/10.1016/s0304-3835(01)00787-x.

25. Firat F, Ozgul M, Turkoz Uluer E, Inan S. Effects of caffeic acid phenethyl ester (CAPE) on angiogenesis, apoptosis and oxidative stress in various cancer cell lines. Biotech Histochem. 2019. https://doi.org/10.1007/s12019-019-1589574.

26. Omene C, Kalac M, Wu J, Marchi E, Frenkel K, O’Connor OA. Propolis and its active component, caffeic acid phenethyl ester (CAPE), modulate breast cancer therapeutic targets via an epigenetically mediated mechanism of action. J Cancer Sci Ther. 2013;5:333–42.

27. Demestre M, Messerli SM, Celli N, Shahhossini M, Kluwe L, Mauthner V, Maruta H. CAPE (caffeic acid phenethyl ester)-based propolis extract (Bio 30) suppresses the growth of human neurofibromatosis (NF) tumor xenografts in mice. Phytother Res. 2009;23:226–30. https://doi.org/10.1002/ptr.2594.
28. Na HK, Wilson MR, Kang KS, Chang CC, Grunberger D, Trosko JE. Restoration of gap junctional intercellular communication by caffeic acid phenethyl ester (CAPE) in a ras-transformed rat liver epithelial cell line. Cancer Lett. 2000;157:31–8. https://doi.org/10.1016/s0304-3835(00)00470-5.

29. Messerli SM, Ahn MR, Kunimasa K, Yanagihara M, Tatelfuji T, Hashimoto K, Mautner V, Uto Y, Hori H, Kumazawa S, et al. Artepillin C (ARC) in Brazilian green propolis selectively blocks oncogenic PAK1 signaling and suppresses the growth of NF tumors in mice. Phytother Res. 2009;23:423–7. https://doi.org/10.1002/ptr.2658.

30. Lee YJ, Kuo HC, Chu CY, Wang CJ, Tseng TH. Involvement of tumor suppressor protein p53 and p38 MAPK in caffeic acid phenethyl ester-induced apoptosis of C6 glioma cells. Biochem Pharmacol. 2003;66:2281–9. https://doi.org/10.1016/j.bcp.2003.07.014.

31. Beauregard AP, Harquail J, Lassalle-Claux G, Belbraouet M, Jean-Francois J, Touaibia M, Robichaud GA. CAPE analogs induce growth arrest and apoptosis in breast cancer cells. Molecules. 2015;20:12576–89. https://doi.org/10.3390/molecules200712576.

32. Chuu CP, Lin HP, Ciaccio MF, Kokontis JM, Hause RJ Jr, Hiipakka RA, Liao S, Jones RB. Caffeic acid phenethyl ester suppresses the proliferation of human prostate cancer cells through inhibition of p70S6K and Akt signaling networks. Cancer Prev Res (Phila). 2012;5:788–97. https://doi.org/10.1158/1940-6207.CAPR-12-0004-T.

33. Liao HF, Chen YY, Liu JJ, Hsu ML, Shieh HJ, Liao HJ, Shieh CJ, Shiao MS, Chen YJ. Inhibitory effect of caffeic acid phenethyl ester on angiogenesis, tumor invasion, and metastasis. J Agric Food Chem. 2003;51:7907–12. https://doi.org/10.1021/jf034729d.

34. Izuta H, Shimazawa M, Tsuruma K, Araki Y, Mishima S, Hara H. Bee products prevent VEGF-induced angiogenesis in human umbilical vein endothelial cells. BMC Complement Altern Med. 2009;9:45. https://doi.org/10.1186/1472-6882-9-45.

35. Kuo YY, Lin HP, Huo C, Su LC, Yang J, Hsiao PH, Chiang HC, Chung CJ, Wang HD, Chang JY, et al. Caffeic acid phenethyl ester suppresses proliferation and survival of TW2.6 human oral cancer cells via inhibition of Akt signaling. Int J Mol Sci. 2013;14:8801–17. https://doi.org/10.3390/ijms14058801.

36. Kuo YY, Lin HP, Huo C, Su LC, Yang J, Hsiao PH, Chiang HC, Chung CJ, Wang HD, Chang JY, et al. Caffeic acid phenethyl ester suppresses proliferation and survival of TW2.6 human oral cancer cells via inhibition of Akt signaling. Int J Mol Sci. 2013;14:8801–17. https://doi.org/10.3390/ijms14058801.

37. Liu CC, Hsu JM, Chuu CP. Caffeic acid phenethyl ester as an adjuvant therapy for advanced prostate cancer. Med Hypotheses. 2013;80:617–9. https://doi.org/10.1016/j.mehy.2013.02.003.

38. Wadhwa R, Nigam N, Bhargava P, Dhanjal JK, Goyal S, Grover A, Sundar D, Ishida Y, Terao K, Kaul SC. Molecular characterization and enhancement of anticancer activity of caffeic acid phenethyl ester by gamma cyclodextrin. J Cancer. 2016;7:1755–71. https://doi.org/10.7150/jca.15170.

39. Motawi TK, Abdelazim SA, Darwish HA, Elbaz EM, Shouman SA. Could caffeic acid phenethyl ester expand the antitumor effect of tamoxifen in breast carcinoma? Nutr Cancer. 2016;68:435–45. https://doi.org/10.1080/01635581.2016.1153669.

40. Motawi TK, Abdelazim SA, Darwish HA, Elbaz EM, Shouman SA. Modulation of tamoxifen cytotoxicity by caffeic acid phenethyl ester in MCF-7 breast cancer cells. Oxid Cell Mol Longev. 2016;2016:3017108. https://doi.org/10.1155/2016/3017108.

41. Matsunaga T, Tsuchimura S, Azuma N, Endo S, Ichihara K, Ikari A. Bee products prevent VEGF-induced angiogenesis in human umbilical vein endothelial cells. BMC Complement Altern Med. 2009;9:45. https://doi.org/10.1186/1472-6882-9-45.

42. Anjaly K, Tiku AB. Radio-modulatory potential of caffeic acid phenethyl ester: a therapeutic perspective. Anticancer Agents Med Chem. 2018;18:468–75. https://doi.org/10.2174/187152061766617113143945.

43. Sari AN, Bhargava P, Dhanjal JK, Putri JF, Radhakrishnan N, Shefrin S, Ishida Y, Terao K, Sundar D, Kaul SC, et al. Combination of withaferin-A and CAPE provides superior anticancer potency: bioinformatics and experimental evidence to their molecular targets and mechanism of action. Cancers. 2020. https://doi.org/10.3390/cancers12051160.

44. Liu X, Wilcken R, Joerger AC, Chuckowree IS, Amin J, Spencer J, Fersht AR. Small molecule induced reactivation of mutant p53 in cancer cells. Nucleic Acids Res. 2013;41:6034–44. https://doi.org/10.1093/nar/gkt305.

45. Joerger AC, Allen MD, Fersht AR. Crystal structure of a superbable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutations. J Biol Chem. 2004;279:1291–6. https://doi.org/10.1074/jbc.M309732000.

46. Protein Preparation Wizard; Epik, Impact, Prime, LigPrep, Glide, Schrödinger, LLC, New York, NY, 2020; Desmond Molecular Dynamics System, D. E. Shaw Research, New York, NY, 2020; Maestro-Desmond Interoperability Tools, Schrödinger, New York, NY. v. 2 (2020). 2020

47. Muller PA, Vousden KH. p53 mutations in cancer. Nat Cell Biol. 2013;15:2–8. https://doi.org/10.1038/ncb2641.

48. Wadhwa R, Takano S, Robert M, Yoshida A, Nomura H, Reddel RR, Mitsui Y, Kaul SC. Inactivation of tumor suppressor p53 by mot-2, a hsp70 family member. J Biol Chem. 1998;273:29586–91. https://doi.org/10.1074/jbc.273.45.29586.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.